Antibody data
- Antibody Data
- Antigen structure
- References [23]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [6]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12308 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- SLC5A5 Monoclonal Antibody (FP5A)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- MA5-12308 targets Sodium Iodide Symporter in IHC (P) and WB applications and shows reactivity with Human samples.
- Antibody clone number
- FP5A
- Concentration
- 0.2 mg/mL
Submitted references Regulation of the Tpo, Tg, Duox2, Pds, and Mct8 genes involved in the synthesis of thyroid hormones after subchronic exposure to sodium nitrate in female Wistar rats.
FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy.
Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses.
Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.
Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death.
Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
Correlation of iodine symporter expression in highly and low malignant cell lines of human breast cancer differed in their sensitivity to doxorubicin.
Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: Promising potential for targeting radiosensitive retinoblastoma.
Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.
Detailed assessment of gene activation levels by multiple hypoxia-responsive elements under various hypoxic conditions.
Long-term effects of hepatocyte growth factor gene therapy in rat myocardial infarct model.
Conserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity.
Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells.
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes.
Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein.
Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer.
SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene.
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma.
Accuracy of myocardial sodium/iodide symporter gene expression imaging with radioiodide: evaluation with a dual-gene adenovirus vector.
Ríos-Sánchez E, González-Zamora A, Gonsebatt Bonaparte ME, Meza Mata E, González-Delgado MF, Zámago Amaro A, Pérez-Morales R
Environmental toxicology 2021 Dec;36(12):2380-2391
Environmental toxicology 2021 Dec;36(12):2380-2391
FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy.
Rathod M, Kelkar M, Valvi S, Salve G, De A
Molecular therapy oncolytics 2020 Dec 16;19:93-104
Molecular therapy oncolytics 2020 Dec 16;19:93-104
Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses.
Koodie L, Robertson MG, Chandrashekar M, Ruth G, Dunning M, Bianco RW, Davydova J
Cancers 2019 Feb 8;11(2)
Cancers 2019 Feb 8;11(2)
Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.
Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA
The Journal of clinical endocrinology and metabolism 2018 Sep 1;103(9):3169-3182
The Journal of clinical endocrinology and metabolism 2018 Sep 1;103(9):3169-3182
Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death.
Wächter S, Damanakis AI, Elxnat M, Roth S, Wunderlich A, Verburg FA, Fellinger SA, Bartsch DK, Di Fazio P
Journal of clinical medicine 2018 Mar 21;7(4)
Journal of clinical medicine 2018 Mar 21;7(4)
Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
Wächter S, Wunderlich A, Greene BH, Roth S, Elxnat M, Fellinger SA, Verburg FA, Luster M, Bartsch DK, Di Fazio P
International journal of molecular sciences 2018 Jul 17;19(7)
International journal of molecular sciences 2018 Jul 17;19(7)
Correlation of iodine symporter expression in highly and low malignant cell lines of human breast cancer differed in their sensitivity to doxorubicin.
Lukianova NY, Andriiv AV, Chekhun VF
Experimental oncology 2016 Sep;38(3):169-71
Experimental oncology 2016 Sep;38(3):169-71
Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: Promising potential for targeting radiosensitive retinoblastoma.
Samuel J, Singh N, Kanwar JR, Krishnakumar S, Kanwar RK
Experimental eye research 2015 Oct;139:108-14
Experimental eye research 2015 Oct;139:108-14
Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.
Lee JW, Min HS, Lee SM, Kwon HW, Chung JK
Nuclear medicine and molecular imaging 2015 Jun;49(2):127-34
Nuclear medicine and molecular imaging 2015 Jun;49(2):127-34
Detailed assessment of gene activation levels by multiple hypoxia-responsive elements under various hypoxic conditions.
Takeuchi Y, Inubushi M, Jin YN, Murai C, Tsuji AB, Hata H, Kitagawa Y, Saga T
Annals of nuclear medicine 2014 Dec;28(10):1011-9
Annals of nuclear medicine 2014 Dec;28(10):1011-9
Long-term effects of hepatocyte growth factor gene therapy in rat myocardial infarct model.
Jin YN, Inubushi M, Masamoto K, Odaka K, Aoki I, Tsuji AB, Sagara M, Koizumi M, Saga T
Gene therapy 2012 Aug;19(8):836-43
Gene therapy 2012 Aug;19(8):836-43
Conserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity.
Li CC, Ho TY, Kao CH, Wu SL, Liang JA, Hsiang CY
Journal of biomedical science 2010 Nov 23;17:89
Journal of biomedical science 2010 Nov 23;17:89
Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells.
Li W, Ain KB
Endocrine-related cancer 2010 Jun;17(2):383-98
Endocrine-related cancer 2010 Jun;17(2):383-98
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
Fortunati N, Catalano MG, Marano F, Mugoni V, Pugliese M, Bosco O, Mainini F, Boccuzzi G
Breast cancer research and treatment 2010 Dec;124(3):667-75
Breast cancer research and treatment 2010 Dec;124(3):667-75
Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, Lindenthal S, Ettore F, Darcourt J, Pourcher T
European journal of endocrinology 2009 Feb;160(2):215-25
European journal of endocrinology 2009 Feb;160(2):215-25
Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
Farnedi A, Eusebi LH, Poli F, Foschini MP
International journal of surgical pathology 2009 Aug;17(4):327-34
International journal of surgical pathology 2009 Aug;17(4):327-34
Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes.
Yeom CJ, Chung JK, Kang JH, Jeon YH, Kim KI, Jin YN, Lee YM, Jeong JM, Lee DS
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008 Sep;49(9):1489-97
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008 Sep;49(9):1489-97
Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein.
Jin YN, Chung HK, Kang JH, Lee YJ, Kimm KI, Kim YJ, Kim S, Chung JK
Cancer biotherapy & radiopharmaceuticals 2008 Oct;23(5):551-60
Cancer biotherapy & radiopharmaceuticals 2008 Oct;23(5):551-60
Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer.
Montiel-Equihua CA, Martín-Duque P, de la Vieja A, Quintanilla M, Burnet J, Vassaux G, Lemoine NR
Cancer gene therapy 2008 Jul;15(7):465-73
Cancer gene therapy 2008 Jul;15(7):465-73
SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene.
Merron A, Peerlinck I, Martin-Duque P, Burnet J, Quintanilla M, Mather S, Hingorani M, Harrington K, Iggo R, Vassaux G
Gene therapy 2007 Dec;14(24):1731-8
Gene therapy 2007 Dec;14(24):1731-8
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
Liu B, Hervé J, Bioulac-Sage P, Valogne Y, Roux J, Yilmaz F, Boisgard R, Guettier C, Calès P, Tavitian B, Samuel D, Clerc J, Bréchot C, Faivre J
Gastroenterology 2007 Apr;132(4):1495-503
Gastroenterology 2007 Apr;132(4):1495-503
A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma.
Liang JA, Chen CP, Huang SJ, Ho TY, Hsiang CY, Ding HJ, Wu SL
Cancer letters 2005 Dec 8;230(1):65-71
Cancer letters 2005 Dec 8;230(1):65-71
Accuracy of myocardial sodium/iodide symporter gene expression imaging with radioiodide: evaluation with a dual-gene adenovirus vector.
Lee KH, Kim HK, Paik JY, Matsui T, Choe YS, Choi Y, Kim BT
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005 Apr;46(4):652-7
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005 Apr;46(4):652-7
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human thyroid gland stained with Sodium Iodide Symporter antibody using peroxidase-conjugate and AEC chromogen. Note cytoplasmic staining of follicular epithelium.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 bHDACi Induces NIS Expression Specifically in BC Cells, but Not in Normal Breast or TC Cells (A) Graphs showing fold difference in NIS transcript levels for ZR-75-1, MCF-7, and ARO cell lines post-bHDACi treatment with respect to their untreated counterparts. Error bar represents SEM; significance determined by t test. *p
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 AR-42 and MS-275 Enhance the NIS Promoter Activity and Expression In Vivo (A) Bioluminescence (BLI) images of representative mouse with orthotopic ZR-75-1 NF tumors showing change in NIS promoter activity in untreated control and AR-42 drug-treated groups. (B) Graph showing BLI signal quantified from control and treated groups, normalized to the respective signals before treatment. Error bar indicates SEM (n = 2).*p
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 bHDACi Differentially Regulates NIS Expression across Organs In Vivo (A) Photomicrographs of NIS IHC performed on mouse thyroid, lung, ovary, stomach, and liver tissues harvested from untreated control or MS-275-treated mouse. DAB staining (brown) and respective H&E-stained images are displayed. (B) Histogram profiles of DAB-stained tissue sections showing NIS intensity profile obtained by using IHC Profiler program. (C) Images of gel picture showing amplified NIS transcripts as a measure of response to VPA and MS-275 drug treatment in various cancer cell lines, i.e., BC (ZR-75-1), lung cancer (A-549), hepatocellular carcinoma (HEPG2), ovarian cancer (A2780), and glioblastoma (U87). beta-actin housekeeping gene is used as loading control.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 3 FIGURE Tsh, Tsh-R, and Nis protein levels in rats exposed to NaNO 3 . (A) Tsh levels measured in serum. (B) Tsh-R protein measured by Western blotting of the thyroid tissue. Molecular weight for TsrR is 87 kDa. (C) Nis protein measured by Western blotting of the thyroid tissue. Predicted molecular weight for Nis functional protein in thyroid is 87 kDa. As control was used beta Actin of 42 kDa. Data are shown as means +- SEM in groups of seven rats. Significant difference by Tukey's multiple comparisons test at p < .05
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Gene expression as an indicator of virus replication in non-human cell lines. ( a ) Rodent and porcine cells were infected with Ad5 and Ad5/3 viruses which express luciferase in a replication-dependent manner (Ad5DeltaE3-Luc and Ad5/3DeltaE3-Luc). Luc activity was determined on days 1, 2, 3 and 4 post infection. Hamster and porcine cells demonstrated time-dependent increase in Luc expression after Ad5 infection, denoting active replication. Only porcine cells showed time-dependent increase in Luc activity after Ad5/3 infection. Trend analysis across the cell lines shows significant difference in rate of change relative to porcine PK15 under same conditions (* p < 0.05; ** p < 0.005). ( b ) Immunofluorescent images of porcine PK15 cells infected with Ad5 and Ad5/3 vectors expressing replication-dependent sodium-iodide-symporter (NIS) and stained for Ad-hexon (green) and NIS (red) proteins, co-localization indicated in yellow (see arrows), mag. 20x. ( c ) Quantitative assessment by Flow Cytometry of PK15 porcine cells expressing NIS. From day 2 to day 5 the percentage of NIS-positive cells increased after infection with both Ad5DeltaE3-NIS and Ad5/3DeltaE3-NIS. The percentage of NIS-positive cells after infection with Ad5/3 was 4-fold greater than with Ad5 ( p < 0.05).